Drug interactions of Ibrutinib

1 Effect of CYP3A Inhibitors on Ibrutinib

The coadministration of Ibrutinib with a strong or moderate CYP3A inhibitor may increase  ibrutinib plasma concentrations. Increased ibrutinib  concentrations may increase the risk of drug-related toxicity.

Dose modifications of Ibrutinib are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors.

Avoid concomitant use of other strong CYP3A inhibitors. Interrupt Ibrutinib if these  inhibitors will be used short-term (such as anti-infectives for seven days or less).

Avoid grapefruit and Seville oranges during Ibrutinib treatment, as these contain strong or  moderate inhibitors of CYP3A.

2 Effect of CYP3A Inducers on Ibrutinib

The coadministration of Ibrutinib with strong CYP3A inducers may decrease ibrutinib  concentrations. Avoid coadministration with strong CYP3A inducers.

from FDA，2024.05